title: Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
abstract: BACKGROUND
  We investigated the effect of rosuvastatin, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
  
  
  METHODS
  The subjects were 24 patients with noncardiogenic cerebral infarction complicated by dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥ 140 mg/dL). Serum lipids and highly sensitive C-reactive protein (hs-CRP) were measured at the start of the study and at 3 and 12 months after the initiation of oral rosuvastatin (5 mg/day). Cardio-ankle vascular index (CAVI), intima-media thickness (IMT), and plaque score (PS) were also determined at the start of the study and at 12 months.
  
  
  RESULTS
  Of the 24 patients admitted, 17 were eligible for statistical analysis. Total cholesterol (TC), LDL-C, and non-high-density lipoprotein cholesterol (non-HDL-C) (mean [standard deviation {SD}], mg/dL) were significantly decreased at 3 months (TC, 149.4 [20.4]; LDL-C, 78.7 [18.6]; non-HDL-C, 94.6 [21.7]) and at 12 months (TC, 154.9 [27.2]; LDL-C, 82.5 [23.3]; non-HDL-C, 100.2 [28.8]) compared with the baseline data (TC, 232.8 [29.7]; LDL-C, 162.2 [21.2]; non-HDL-C, 183.0 [27.7]). The serum hs-CRP level (mean [SD], ng/mL) was 1053.1 [818.8] at baseline, 575.2 [481.8] at 3 months, and 488.1 [357.7] at 12 months. The decrease in this parameter at 12 months was statistically significant. There was a decrease, although not statistically significant, in CAVI (mean [SD]) at 12 months (right [Rt.] 8.7 [.9]; left [Lt.] 8.6 [1.0]), compared with baseline (Rt. 9.1 [1.1]; Lt. 9.0 [1.1]). The max-IMT (mean [SD], mm) was (Rt. 2.11 [.97]; Lt. 2.01 [.75]) at baseline and (Rt. 2.18 [.82]; Lt. 2.06 [.79]) at 12 months of study treatment. The PS (mean [SD], mm) was 8.93 [4.33] at baseline and 9.61 [4.79] at 12 months; neither parameter showed a significant change.
  
  
  CONCLUSIONS
  Rosuvastatin at 5 mg/day significantly reduced serum levels of TC, LDL-C, non-HDL-C, and hs-CRP in dyslipidemic patients with cerebral infarction. No significant change in CAVI, max-IMT, or PS was noted after the study treatment.
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address: ideguchi@saitama-med.ac.jp.
authors: Ichiro
authors: I
authors: Deguchi
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Yohsuke
authors: Y
authors: Horiuchi
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Takeshi
authors: T
authors: Hayashi
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Yoshihide
authors: Y
authors: Sehara
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Yuji
authors: Y
authors: Kato
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Yasuko
authors: Y
authors: Ohe
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Takuya
authors: T
authors: Fukuoka
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Hajime
authors: H
authors: Maruyama
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Hiroyasu
authors: H
authors: Sano
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Yuito
authors: Y
authors: Nagamine
authors: Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Norio
authors: N
authors: Tanahashi
mesh_terms: D000328:Adult; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy; D002097:C-Reactive Protein / Q000032:analysis*; D059168:Carotid Intima-Media Thickness; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000209:etiology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D002784:Cholesterol
keywords: Rosuvastatin; arteriosclerosis; cerebral infarction; dyslipidemia